Cervical Cancer Breakthrough: MSD Pushes for Wider Prevention & Care Alliances!

MSD has issued a compelling call for augmented private-sector participation in Nigeria's determined efforts to eradicate cervical cancer. This urgent appeal underscores the necessity for comprehensive partnerships to bolster prevention strategies, expand screening initiatives, enhance treatment options, and secure sustainable financing mechanisms. The significant plea was made during a pivotal policy roundtable, meticulously orchestrated by MSD in collaboration with Africa Health Business (AHB). Held in Abuja, the event was themed, "Accelerating Cervical Cancer Elimination in Nigeria: Uniting Public and Private Sectors for Equitable Access," highlighting the imperative of a synergistic approach between various stakeholders.

Vuyo Mjekula, Director of External Affairs for Sub-Saharan Africa at MSD, articulated Nigeria's commendable strides in Human Papillomavirus (HPV) vaccination. She noted that since the national program's inception in 2023, an impressive figure of over 18 million girls have received HPV vaccinations. Mjekula lauded this achievement as a robust foundation for the accelerated elimination of cervical cancer, yet emphasized the critical need to extend these gains beyond vaccination to encompass robust screening, timely early diagnosis, and effective treatment protocols. Her statements resonated with the broader understanding that a multi-pronged strategy is essential for complete eradication.

Mjekula further elaborated on the evolving global funding landscape, which increasingly necessitates domestic resource mobilization. This shift, she argued, underscores the heightened importance of stronger and more integrated partnerships involving governmental bodies, the private sector, civil society organizations, and other relevant stakeholders. To mitigate fragmentation and optimize the deployment of available resources, she advocated for the inclusion of private-sector representatives within national cervical cancer task forces, collaborative partnerships, and technical working groups. "There’s a huge opportunity to break down fragmentation, galvanise and integrate resources so that the resources can be deployed to the most impactful areas and build efficiencies in general," Mjekula asserted, advocating for a cohesive national response.

A core tenet of MSD's advocacy, as highlighted by Mjekula, involves the integration of cervical cancer screening and other vital preventive services directly into women's routine healthcare frameworks. This approach moves away from the fragmented model where maternal health, HIV prevention, sexual and reproductive health, and other related services are often treated as isolated interventions. Such integration aims to streamline access to care and ensure that preventive measures are routinely accessible. Furthermore, MSD has actively supported catch-up HPV vaccination programs, targeting girls up to the age of 20 who may have missed out during the initial national program rollout. The company is also collaborating with Gavi and UNICEF to facilitate access to higher-valency HPV vaccines across Africa.

Demonstrating its long-term commitment to healthcare in Nigeria, MSD has invested over $44 million in the country during the past decade through its "MSD for Mothers" initiative. This significant investment has primarily supported civil society organizations dedicated to maternal healthcare. Beyond cervical cancer, MSD is also actively engaged with City Cancer Challenge in Abuja, working to pinpoint existing gaps and devise innovative solutions for enhancing oncology services more broadly, thus contributing to a comprehensive cancer care ecosystem in the nation.

Echoing and reinforcing these sentiments, Dr. Rufai Ahmed Garba, Director of Disease Control and Immunisation at the National Primary Health Care Development Agency (NPHCDA), confirmed Nigeria's impressive vaccination statistics. He stated that more than 18 million adolescent girls have been vaccinated against HPV, effectively covering approximately 76 percent of the target population. Dr. Garba reiterated that the HPV vaccine was officially incorporated into the national program in October 2023 and has since become an integral part of routine immunization, offering free vaccination to nine-year-old girls at public health facilities nationwide.

However, Dr. Garba cautioned that vaccination alone, while crucial, will not suffice to eliminate cervical cancer. He vehemently stressed the indispensable need to fortify screening initiatives, ensure early diagnosis, provide effective treatment, and implement robust follow-up care mechanisms. Highlighting the dire consequences of delayed intervention, he disclosed alarming statistics: Nigeria experiences approximately 12,000 new cervical cancer cases and nearly 8,000 deaths annually. This stark reality underscores the urgent requirement for a holistic and comprehensive response to the disease. "If it is not diagnosed early, if it is not treated early, it leads to death. So, that’s what all of this is about—not just the vaccination, which NPHCDA does, but also how we are able to get women to screen them, to catch them early, treat them and follow them up till they actually get better," Dr. Garba emphasized, articulating the full spectrum of care needed.

To enhance accessibility and outreach, the Nigerian government has proactively adopted school-based vaccination programs and community outreach initiatives. Additionally, the establishment of adolescent-friendly health services is designed to provide secure and welcoming environments where young people can readily access vital information and preventive care. Nigeria has officially recognized cervical cancer elimination as a national health priority, aligning its strategic framework with the World Health Organization’s ambitious 90-70-90 targets. These targets encompass achieving 90% HPV vaccination coverage, 70% screening coverage, and 90% access to treatment. The policy roundtable effectively convened a diverse array of stakeholders, including representatives from government, healthcare, public health, the private sector, and prominent cancer advocacy groups, all united in discussing collaborative strategies to strengthen Nigeria’s entire cervical cancer prevention and care continuum.